Article Figures & Data
Figures
- Figure 1 Study Concept
Patients were prospectively recruited by telephone call over a period of 15 consecutive week days. The baseline MG-ADL score and a blood sample to assess NP-IgG serology and IGRA was obtained before the first dose was administered. Seven days after the first dose, a second MG-ADL score was obtained. The second dose of the vaccine was administered 28 days after the first dose, following the manufacturer's recommendations. A third MG-ADL score was administered a week after the second dose. For all 3 MG-ADL scores, patients were asked about symptoms in the previous 7 days to score each MG-ADL item. A second blood sample was obtained 90 days after the second dose, and IGRA and spike-IgG were determined. During a 6-month-follow-up, COVID-19 symptoms were telematically assessed in all patients. COVID-19 = coronavirus disease 2019; IgG = immunoglobulin G; IGRA = interferon gamma release assay; MG-ADL = myasthenia gravis activities of daily living score; NP-IgG serology = SARS-CoV-2 nucleocapsid protein antibodies serology; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; spike-IgG serology = SARS-CoV-2 spike protein 1 IgG antibodies serology.
- Figure 2 MG-ADL Score After Vaccination in Accordance With Baseline MG-ADL Score
Boxplot representing the MG-ADL scores after the first and second doses. The vertical axis represents the MG-ADL score reported by the patients, from minimum to maximum. The horizontal axis represents the MG-ADL score at baseline less than 3 (yellow box) or equal to or greater than 3 (orange box). At both time points, patients with an MG-ADL at baseline of 3 points or more had a higher MG-ADL score after each dose, with higher ranges reflecting greater variability in that group. MG-ADL score = myasthenia gravis activities of daily living score.
- Figure 3 Antispike-IgG Antibody titers and IGRA Positivity After Vaccinations According to Treatment Group
(A) Antispike-IgG antibody titers in IU/mL is represented in the dot plot for each treatment group. The mean titer is represented by a black line for each group. Threshold line represents the 5 IU/mL cutoff for positivity. (B) Blue bars indicate the percentage of IGRA-positive patients. The percentage of IGRA-negative patients is indicated in yellow bars. Indeterminate IGRA are represented in green bars. IGRA resulting in borderline tests are represented in purple bars. IgG = immunoglobulin G; IGRA = interferon gamma release assay; IST = immunosuppressant therapy.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
